Neuland Labs -
Broad brush highlights from management’s Q1 commentary -
Expecting moderate growth this FY. Growth in last two FY’s was exceptionally high. Won’t get repeated this FY. Management asked the audience to draw their own conclusion from this ( my deduction - going by the management’s tone, I guess they are hinting at 10-15 pc kind of growth rates for current FY - to be taken with a bucket of salt )
Also guided at pick up in growth rates in FY 26
BioSecure act should be a huge tailwind going forward for the CDMO Industry. Seeing increased customer visits as a led indicator of customer’s interests wrt Indian players
Traditionally, Neuland did most of its innovation related work with smaller Bio-Tech companies. As these companies are being acquired by big Pharma companies, Neuland hopes to become a household name with big Pharma as well ( in next 3-4 yrs )
CDMO Pipeline -
Current number of molecules in Phase 3 @ 07 ( 03 APIs + 04 Intermediates )
No of commercial molecules @ 18 ( 08 APIs + 10 Intermediates )
No of molecules in pre-commercial stage @ 14 ( 08 APIs + 06 Intermediates )
Disc: holding from lower levels, biased, my largest portfolio position, not SEBI registered, not a buy / sell recommendation
| Subscribe To Our Free Newsletter |
